In the present study, changes in uric acid levels based on baseline uric acid levels and changes in eGFR in response to the changes in uric acid levels in type 2 diabetes patients treated with the SGLT2 inhibitor luseogliflozin were observed, matched to patient background. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.